Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis.
Evangelos DigkasAnthony Jagri TabiimDaniel SmithAntonios ValachisPublished in: Targeted oncology (2022)
In patients with melanoma or NSCLC, the clinical value of checkpoint inhibitors is evident in both RCTs and real-world settings. Some differences in response or toxicity rates in favor of RWE mainly reflects the inherent difficulties in evaluating these outcomes in RWE studies.
Keyphrases
- advanced non small cell lung cancer
- dna damage
- epidermal growth factor receptor
- cell cycle
- oxidative stress
- papillary thyroid
- skin cancer
- double blind
- squamous cell
- phase iii
- clinical trial
- basal cell carcinoma
- oxide nanoparticles
- type diabetes
- cell proliferation
- randomized controlled trial
- adipose tissue
- case control
- insulin resistance